(FM) Oncología
Departamento académico
Iñaki
Etxeberria Ruesta
Publicaciones en las que colabora con Iñaki Etxeberria Ruesta (20)
2023
-
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity
Cancer immunology research, Vol. 11, Núm. 2, pp. 184-198
-
mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy
Cell Reports Medicine, Vol. 4, Núm. 3
2022
-
A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β
Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157
2021
-
Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic
Proceedings of the National Academy of Sciences of the United States of America, Vol. 118, Núm. 26
-
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Nature Communications, Vol. 12, Núm. 1
2020
-
CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity
Immunity, Vol. 52, Núm. 5, pp. 856-871.e8
-
Cellular cytotoxicity is a form of immunogenic cell death
Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1
-
Human CD8 T cells are susceptible to TNF-mediated activation-induced cell death
Theranostics, Vol. 10, Núm. 10, pp. 4481-4489
2019
-
Cytokines in clinical cancer immunotherapy
British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15
-
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
Journal for ImmunoTherapy of Cancer, Vol. 7, Núm. 1
-
Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells
Cancer cell, Vol. 36, Núm. 6, pp. 613-629
-
TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies
Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631
-
Twists and turns to translating 4-1BB cancer immunotherapy
Science Translational Medicine, Vol. 11, Núm. 496
2018
-
Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4–1BB)
OncoImmunology, Vol. 7, Núm. 1
-
Intratumoral immunotherapy with XCL1 and sFlt3L encoded in recombinant semliki forest virus–derived vectors fosters dendritic cell–mediated t-cell cross-priming
Cancer Research, Vol. 78, Núm. 23, pp. 6643-6654
-
Revisiting interleukin-12 as a cancer immunotherapy agent
Clinical Cancer Research, Vol. 24, Núm. 12, pp. 2716-2718
2017
-
Anti-CD137 and PD-1/PD-L1 antibodies en route toward clinical synergy
Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5326-5328
-
Intercellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule Are Induced by Ionizing Radiation on Lymphatic Endothelium
International Journal of Radiation Oncology Biology Physics, Vol. 97, Núm. 2, pp. 389-400
2016
-
Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy
European Journal of Immunology, Vol. 46, Núm. 3, pp. 513-522
-
Immunotherapy of cancer visualized by live microscopy: Seeing is believing
Clinical Cancer Research, Vol. 22, Núm. 17, pp. 4277-4279